Page 91 - 2019_01-Haematologica-web

JAK2V617F endothelial cells are pro-thrombotic
megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. Platelets. 2014;25(7):539- 547.
33. Etulain J, Martinod K, Wong SL, Cifuni SM, Schattner M, Wagner DD. P-selectin pro- motes neutrophil extracellular trap forma- tion in mice. Blood. 2015;126(2):242-246.
34. Martinod K, Wagner DD. Thrombosis: tan- gled up in NETs. Blood. 2014;123(18):2768- 2776.
35. Kim KJ, Kwon SH, Yun JH, et al. STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression. Oncogene. 2017;36(39):5445-5459.
36. Helman R, Pereira WO, Marti LC, et al. Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari syndrome without myeloproliferative neoplasm. Br J Haematol. 2018;180(3):443-445.
37. Piaggio G, Rosti V, Corselli M, et al. Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecu- lar clonality marker. Blood. 2009;114(14):3127-3130.
38. Yoder MC, Mead LE, Prater D, et al.
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801-1809.
39. Sozer S, Ishii T, Fiel MI, et al. Human CD34+ cells are capable of generating nor- mal and JAK2V617F positive endothelial like cells in vivo. Blood Cells Mol Dis. 2009;43(3):304-312.
40. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood. 2006;108(1):184-191.
41. Cokic VP, Beleslin-Cokic BB, Noguchi CT, Schechter AN. Hydroxyurea increases eNOS protein levels through inhibition of proteasome activity. Nitric Oxide. 2007;16(3):371-378.
42. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317-1322.
43. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombo- cythemia: a single institutional study of 605
patients. Leukemia. 2007;21(2):270-276. 44. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood.
2005;105(7):2664-2670.
45. Tefferi A, Rumi E, Finazzi G, et al. Survival
and prognosis among 1545 patients with contemporary polycythemia vera: an inter- national study. Leukemia. 2013;27(9):1874- 1881.
46. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin medi- ates the adhesion of sickle erythrocytes to the endothelium. Blood. 2001;98(6):1955- 1962.
47. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429-439.
48. Etheridge SL, Roh ME, Cosgrove ME, et al. JAK2V617F-positive endothelial cells con- tribute to clotting abnormalities in myelo- proliferative neoplasms. Proc Natl Acad Sci USA. 2014;111(6):2295-2300.
49. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in trans- genic mice. Blood. 2008;111(8):3931-3940.
haematologica | 2019; 104(1)
81